Welcome to our dedicated page for Relmada Therapeutics SEC filings (Ticker: RLMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Relmada Therapeutics’ path toward bringing esmethadone (REL-1017) to patients means reading dense SEC disclosures packed with clinical trial tables and R&D spend footnotes. Searching for when management raises capital, files an 8-K after a Phase 3 readout, or sells shares through Form 4 can feel like decoding a new molecule.
Stock Titan’s AI steps in. Our engine turns every Relmada Therapeutics annual report 10-K simplified, each Relmada Therapeutics quarterly earnings report 10-Q filing, and every Relmada Therapeutics 8-K material events explained into plain-language briefs. The platform flags Relmada Therapeutics insider trading Form 4 transactions seconds after they hit EDGAR and groups them into clear charts. Prefer narrative? Understanding Relmada Therapeutics SEC documents with AI means you’ll see R&D burn, milestone payments, and cash runway highlighted automatically.
Wondering about dilution risk, royalty obligations, or executive pay? Dive into the Relmada Therapeutics proxy statement executive compensation section with pop-up tooltips, or scan Relmada Therapeutics earnings report filing analysis for quarter-over-quarter cash use. Real-time alerts on Relmada Therapeutics Form 4 insider transactions allow you to watch when key scientists exercise options. All filings—S-3 financings, 424B5 offerings, clinical 8-Ks—arrive as they’re accepted, so you never miss critical disclosures.
Need Relmada Therapeutics SEC filings explained simply? Whether you’re comparing trial costs, monitoring Relmada Therapeutics executive stock transactions Form 4, or auditing licensing commitments, our complete archive keeps every document within two clicks. Complex biotech disclosures, clarified.
Schedule 13G/A filed for Relmada Therapeutics (RLMD) discloses beneficial ownership stakes held by Squadron-related filers. Squadron Master Fund LP reports shared beneficial ownership of 2,914,495 shares representing 8.8% of the outstanding common stock. Squadron Capital Management LLC and William Blank each report shared beneficial ownership of 3,298,500 shares, representing 9.9% of the class. The filing clarifies that Squadron Capital Management serves as adviser to funds that hold these shares and that Mr. Blank may be deemed to have investment and voting discretion, while expressly disclaiming beneficial ownership under Rule 13d-4. The ownership percentages are calculated using an issuer-stated share count of 33,191,622 shares outstanding.
Relmada Therapeutics, Inc. (NASDAQ: RLMD) filed a Form 8-K on 7-Aug-2025 announcing Item 2.02 (Results of Operations) and Item 7.01 (Reg FD).
- The company furnished, but did not file, a press release (Ex. 99.1) containing a corporate update and preliminary, unaudited Q2 2025 results for the period ended 30-Jun-2025.
- A conference call and webcast are scheduled for 7-Aug-2025 at 4:30 PM EDT to discuss the update.
- Full unaudited financial statements will appear in the forthcoming Form 10-Q.
- An updated corporate presentation (Ex. 99.2) was also furnished.
- No quantitative financial metrics, guidance, or transactional details are included in the 8-K itself; all figures reside in the referenced exhibits.
The furnished information is not deemed “filed” under the Exchange Act and therefore carries reduced liability. Investors must consult Exhibits 99.1 and 99.2 or the upcoming 10-Q for substantive financial data.
Relmada Therapeutics (RLMD) Q2-25 10-Q snapshot: The company remains pre-revenue and reported a Q2 net loss of $9.9 m (-44% YoY) and a 6-month loss of $27.4 m (-31% YoY) after sharply reducing R&D spend following the wind-down of its REL-1017 and psilocybin programs. Operating expenses fell 46% YoY to $10.2 m for the quarter.
Balance-sheet pressure intensified. Cash & cash equivalents dropped to $1.35 m (vs. $3.86 m YE-24) while short-term investments fell to $19.3 m (vs. $41.1 m), leaving $20.6 m of liquid resources. With $24.5 m operating cash burn in H1 and no revenue, management warns of substantial doubt about going-concern status.
Key corporate actions:
- Acquired Phase-2b-ready Sepranolone for €3 m cash.
- Licensed NDV-01 (Phase 2 NMIBC) for $3.5 m cash plus 3.0 m shares (≈10% dilution) and up to $200 m milestones; early Phase 2 data show 90% 6-month CR.
- Terminated esmethadone and psilocybin programs to focus resources on the new assets.
- Received Nasdaq bid-price deficiency notice; listing transferred to Nasdaq Capital Market with cure period to 19 Jan 2026.
Capital structure: Shares outstanding rose to 33.2 m (vs. 30.2 m YE-24); options outstanding 14.2 m; warrants 0.75 m. No ATM sales to date. Equity now stands at $15.9 m (vs. $35.5 m).
Outlook: Management is evaluating financing alternatives and may scale trial activity; upcoming catalysts include 9- and 12-month NDV-01 Phase 2 read-outs (2H-25) and planned IND for US trials in 1H-26.
Relmada Therapeutics, Inc. (RLMD) – Form 4 insider filing: The company’s Chief Financial Officer, Maged Shenouda, was granted stock options for 600,000 common shares on 06/26/2025. The options carry an exercise price of $0.67 per share and will vest in 16 equal quarterly installments beginning 09/26/2025, fully vesting by 06/26/2035. Following the grant, Shenouda beneficially owns 600,000 derivative securities, reported as direct ownership. No shares were purchased or sold in the open market; this filing records an equity incentive award, aligning executive compensation with future shareholder value.
Relmada Therapeutics, Inc. (RLMD) filed a Form 4 disclosing a new equity award to director John Glasspool. On 06/26/2025, Glasspool received 100,000 non-qualified stock options with an exercise price of $0.67 per share. The options vest in 16 equal quarterly installments starting 09/26/2025 and expire on 06/26/2035. No common shares were bought or sold; the only reported transaction is the option grant, leaving Glasspool with 100,000 derivative securities held directly. The filing indicates normal onboarding compensation and modest potential dilution relative to RLMD’s outstanding share count (not provided in the document). Investors should view the grant as routine governance practice that aligns the new director’s incentives with long-term shareholder value without any immediate cash outlay or ownership change.
FAQ
What is the current stock price of Relmada Therapeutics (RLMD)?
What is the market cap of Relmada Therapeutics (RLMD)?
